2 results
Approved WMOCompleted
To assess uptake of 18F-PD-L1 and 89Zr- nivolumab in tumor lesions.
Approved WMOCompleted
Primary:To demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks compared to remaining on ABC/DTG/3TC (or DTG and an approved dual-NRTI scheme) over 48 weeks.Secondary:To…